Discontinued drugs in 2012: cardiovascular drugs

Abstract

The continued high rate of cardiovascular morbidity and mortality has attracted wide concern and great attention of pharmaceutical industry. In order to reduce the attrition of cardiovascular drug R&D, it might be helpful recapitulating previous failures and identifying the potential factors to success. This perspective mainly analyses the 30 cardiovascular drugs dropped from clinical development in 2012. Reasons causing the termination of the cardiovascular drugs in the past 5 years are also tabulated and analysed. The analysis shows that the attrition is highest in Phase II trials and financial and strategic factors and lack of clinical efficacy are the principal reasons for these disappointments. To solve the four problems (The ‘better than the Beatles’ problem, the ‘cautious regulator’ problem, the ‘throw money at it’ tendency and the ‘basic researchbrute force’ bias) is recommended as the main measure to increase the number and quality of approvable products.

Keywords::

• ACT-280778
• apadenoson
• atopaxar
• AZD-2927
• BI-204
• CXL-1020
• CytoFab
• dyslipidemia therapy – Veloxis pharmaceuticals
• eprotirome
• GED-aPC
• granotapide
• iferanserin – ventrus
• LCP-AtorFen
• MK-0524B
• MP-136
• NCX-226
• NCX-6560
• PF-3882845
• REGN-728
• RG-7236
• RG-7273
• Rusalatide acetate
• sitagliptin + atorvastatin
• tagatose – spherix
• TAK-591
• TB-402
• TC-5214
• tezosentan
• varespladib methyl
• varespladib sodium

Acknowledgement

H-P Zhao and H-M Jiang contributed equally to this work.

Notes

This box summarizes key points contained in the article.